April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Ranibizumab treatment outcome in visual impairment due to myopic choroidal neovascularization: RADIANCE subgroup analysis based on baseline ocular characteristics
Author Affiliations & Notes
  • Nicolas Leveziel
    Ophthalmology, University Hospital of Poitiers, Poitiers, France
  • Adnan Tufail
    Moorfields Eye Hospital, London, United Kingdom
  • Hyeong Gon Yu
    Ophthalmology, Seoul National University College Medicine, Seoul, Republic of Korea
  • You-xin Chen
    Ophthalmology, Peking Union Medical College Hospital, Beijing, China
  • Frank G Holz
    Ophthalmology, University of Bonn, Bonn, Germany
  • Claudia Leteneux
    Novartis Pharma AG, Basel, Switzerland
  • Stefan Pilz
    Novartis Pharma AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships Nicolas Leveziel, Bayer (C), Bayer (F), Novartis (C), Thea (C), Thea (F); Adnan Tufail, Alcon (C), Alcon (R), Allergan (C), Allergan (F), Allergan (R), Bayer (C), Heidelberg Engineering (C), Novartis (C), Novartis (F), Novartis (R), Oculogics (C), Oculogics (I), Pfizer (C), Roche (C), Thrombogenics (C), Thrombogenics (F), Thrombogenics (R); Hyeong Gon Yu, Allergan (C), Bayer (C); You-xin Chen, Novartis (C), Novartis (R); Frank Holz, Acucela (C), Acucela (F), Allergan (C), Allergan (F), Bayer (C), Bayer (F), Boehringer Ingelheim (C), Genentech (C), Genentech (F), Heidelberg Engineering (C), Heidelberg Engineering (F), Merz (C), Novartis (C), Novartis (F), Optos (F), Roche (C), Zeiss (F); Claudia Leteneux, Novartis (E); Stefan Pilz, Novartis (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4956. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicolas Leveziel, Adnan Tufail, Hyeong Gon Yu, You-xin Chen, Frank G Holz, Claudia Leteneux, Stefan Pilz, RADIANCE Study Group; Ranibizumab treatment outcome in visual impairment due to myopic choroidal neovascularization: RADIANCE subgroup analysis based on baseline ocular characteristics. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4956.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

The RADIANCE study evaluated the efficacy and safety of two different ranibizumab 0.5 mg regimens versus verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic choroidal neovascularization (CNV). Both ranibizumab regimens were superior to vPDT at Month 3 (primary endpoint was met) and were effective in improving and sustaining best-corrected visual acuity (BCVA) over 12 months. In a post-hoc analysis, the baseline ocular conditions and the associated exposure and treatment benefits with respect to BCVA were explored in patients who received ranibizumab retreatment, guided by disease activity criteria according to the approved ranibizumab label for treatment of visual impairment due to CNV secondary to pathologic myopia (myopic CNV).


Patients (N=277) were randomized 2:2:1 to Group (G) 1 (ranibizumab treatment guided by VA stabilization), G2 (ranibizumab treatment guided by disease activity), or G3 ( vPDT and as of Month 3, ranibizumab and/or vPDT at investigator’s discretion). BCVA outcomes and treatment exposure of G2 were analyzed by descriptive statistics for the following baseline categories: lesion area (<1.3mm2/1.3-<3.4mm2/≥3.4mm2); CNV lesion area (<0.8mm2/0.8-<2.4mm2/≥2.4mm2); refraction sphere (<10 diopters [D]/10-<20D/≥20D) and axial length (<28mm/28-<30mm/≥30mm). The main outcomes were mean change in BCVA from baseline and number of injections up to M12.


Ranibizumab treatment led to BCVA improvement across the subgroups analyzed. The BCVA outcomes observed in the subgroups at month 12 were in accordance with that of the overall study population. Mean change in BCVA from baseline and the median numbers of injections received at Month12 are presented in Table 1


Ranibizumab treatment was effective in improving the BCVA outcomes in all the subgroups. Regardless of the severity of myopic CNV at baseline, the BCVA gains observed at Month 12 were similar across the subgroups to the overall study population, while there was an inter individual variability in the number of injections required to achieve these outcomes

Keywords: 453 choroid: neovascularization • 605 myopia • 754 visual acuity  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.